Ricardo Grieshaber-Bouyer

Join this session to hear the thoughts of experts who have successfully moved precision therapies from the oncology world into autoimmune diseases:

• Discussing whether the therapeutic goal should be complete depletion of peripheral B-cells or elimination of tissue resident B-cells that drive local pathology
• Addressing the risks associated at various level of depletion such as elevated BAFF
• Debating whether targeted depletion of specific pathogenic subsets is superior to non-selective deep depletion

• Securing Centre’s of Excellence with necessary oncology and rheumatology clinical expertise for patient screening lymphodepletion and toxicity management
• Addressing the competitive landscape around securing sites and managing site capacity that can risk delaying trial activation and delaying patient enrolment
• Improving patient enrolment practices through streamlining the patient journey, site education and increasing the centralization of trials to be more accessible